FDA disapproves Novartis’s Biosimilar drug, Roche’s fears alleviated
Category: #health  By Saipriya Iyer  Date: 2018-05-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

FDA disapproves Novartis’s Biosimilar drug, Roche’s fears alleviated

Roche AG, a Switzerland based healthcare organization, seems to have breathed a sigh of relief with the FDA refusing to grant immediate approval to Novartis’s biosimilar form of Rituxan. According to Novartis’s Sandoz Unit, its copy of Rituxan – the biosimilar medicine used for treating blood cancers has received a complete response letter from the U.S. regulators. Seemingly this is the second case of FDA disapproving the cheaper versions of biotech cancer medicines.

For the record, last month, the FDA had disapproved Rituxan’s biosimilars manufactured jointly by Teva & Celltrion. FDA’s decision, say experts, is certain to boost Roche’s business across the U.S. pharmaceutical market. Indeed, as per statistics, Roche earns nearly USD 4 billion from the sales of Rituxan across the U.S.

Analysts claim that Roche could have incurred a loss of nearly USD 150 million in 2018 across the U.S. if the biosimilar versions of the brand would have been approved by the U.S. FDA.

Incidentally, biosimilar copies of Rituxan have received a green signal from the European regulatory bodies, where the biosimilars manufactured by both Novartis & Celltrion are easily available. It has been claimed that the easy access of Rituximab’s biosimilars in Europe are cutting down the profits of Roche in the region. Reportedly, the sales of Rituximab, a brand of Rituxan, had dipped by nearly 44% in Europe during the first quarter of 2018.

As per authentic sources, the tough competition observed across the biosimilars industry & the stringent focus of investors to pour in capital in the firms manufacturing biosimilar medicines has threatened the sales prospects of the original drug manufacturers such as AbbVie and Roche AG.

For the record, Sandoz mentioned that it is currently in the process of evaluating FDA’s response letter and will stand strong behind the evidence that the regulatory submission has included for its biosimilar.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Foodics enters Egypt market by setting an on-ground presence in Cairo
Foodics enters Egypt market by setting an on-ground presence in Cairo
By Saipriya Iyer

Saudi Arabia-based restaurant management platform Foodics, has announced that it has entered the Egyptian market by creating an on-the-ground presence in Cairo.  The expansion comes after the company raised USD 4 ...

Food Emulsifiers Market to Witness an Appreciable Growth By 2026
Food Emulsifiers Market to Witness an Appreciable Growth By 2026
By Saipriya Iyer

This advanced report on the Food Emulsifiers Market includes of an in-depth overview of this business sphere. Alongside, details of the present market size and status have been given. The report aims to provide substantial updates on the market, p...

Bharat Biotech reveals positive data from animal trial of Covaxin
Bharat Biotech reveals positive data from animal trial of Covaxin
By Saipriya Iyer

Bharat Biotech, an Indian biotechnology company, has reportedly revealed positive results from the animal trial of Covaxin, India’s COVID-19 vaccine candidate.

In the animal t...